- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test | ||
| Fr | AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond | ||
| Fr | Teva saddles up as stalking horse bidder for bankrupt BioXcel's neuroscience portfolio | ||
| Fr | Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact | ||
| Do | CEPI backs push to bring Egyptian biotech's Ebola vaccine into clinic to curb fast-growing outbreak | ||
| Do | Osivax bags flu vaccine rights to pursue combination shot vision | ||
| Mi | JATT mastermind launches latest biotech-focused SPAC via $60M IPO | ||
| Mi | Hansoh heralds China's move from 'follower' to 'frontrunner' in biopharma race | ||
| Mi | Spyre's rheumatoid arthritis plan toppled by subpar TL1A data | ||
| Mi | SK Biopharma pens $795M deal to usher Biohaven's epilepsy therapy towards hoped-for 2029 launch | ||
| Di | Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal | ||
| Di | Capricor secures reprieve as FDA extends DMD cell therapy review | ||
| Mo | TME holds onto $1B dream for brain cancer drug as search for partners nears conclusion | ||
| Mo | Spruce's successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug | ||
| Mo | Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings | ||
| Mo | Roche pens $2.5B pact for Hanmi's clinical-stage obesity drug targeting less-explored mechanism | ||
| 21.08. | Werewolf Therapeutics transforms into Ambros Therapeutics via reverse merger to support phase 3 push for rare disease drug | ||
| 20.08. | Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease | ||
| 20.08. | Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact | ||
| 19.08. | Trump looks set to tap White House aide Heidi Overton as next FDA commissioner | ||
| 19.08. | Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein | ||
| 18.08. | Merck and Sarah Cannon team up to boost oncology trial efficiency | ||
| 18.08. | Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss | ||
| 18.08. | BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca | ||
| 17.08. | Regeneron ends eye disease trial for anti-CD3 antibody following safety review |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.